PathHunter® Cell-based Assays for Human Interleukins

Functional Assays for >85% of Human Interleukins and Their Receptors


DiscoverX offers a comprehensive portfolio of cell based assays to enable the study and targeting of human interleukin proteins and their receptors. The assays are designed to be highly specific, with a simple protocol, large signal to noise ratio, high matrix tolerance and have high reproducibility. This has enabled their broad usage in functional screening, functional characterization, QC lot release assays and neutralizing antibody studies.


Key Benefits

  • Functional Assay – Identify & prioritize leads 
  • Ready to use – Save 3-6 months in assay development 
  • Fast Results – Increase lab efficiency 
  • Simple Protocol – Easy to use & implement 
  • Highly Specific – Screen crude lysates
  • Broad Applications – Screening & Lot Release Assays

Assay Protocol


Highly Specific Assays for Interleukin Receptors Across Multiple Families

Representative examples of assays for interleukin receptors from 6 different families of interleukins / receptors. Each plot shows a dose response for the relevant ligand(s) in a given assay from the indicated family. Data plotted are mean RLU and standard deviation from at least triplicate wells for each dose. These assays are characterized by robust assay windows and low CVs.

Verified with Marketed Therapeutics

A Response of IL23R assay to the therapeutic antibody Ustekinumab or Stelara® (Stelara is a registered trademark of Janssen/Centacor) used to treat inflammatory diseases induced by IL-23 or IL-12. The assay has been tested with two different concentrations of IL-23 agonist, at EC80 and EC50 of the agonist response. B Cell-based assay for detecting stimulation and inhibition of IL-6 signaling through the membrane-bound IL-6R. Assay responds to IL-6 with an EC50 of 1.26ng/ml, while tocilizumab (a therapeutic antibody targeting IL-6R) inhibits IL-6-induced dimerization. C Inhibition of IL-6-dependent proliferation of KPMM2 cells with Tocilizumab. IC50 of 1ug/ml for Tocilizumab obtained with a stimulation dose of 1ng/ml (red arrow) is consistent with the IC50 sub value for tocilizumab in the IL6R dimerization assay (as in figure B) run with the same stimulation condition.  Figure adopted from Mihara et al., (2005) Int. Immunopharmacology 5: 1731-40.

Assay List

Ligand Assay Mechanism Cell Line Bioassay Kit eXpress Kit Ligand Synonyms
CLCF1 - Contact Us     CLCF1 ; BSF-3; BSF3; CISS2; CLC; NNT-1; NNT1; NR6
CNTF - Contact Us     CNTF ; HCNTF
CTF1 - Contact Us     CTF1
G-CSF SH2 Recruitment 93-0809C3   93-0809E3CP16M CSF3; G-CSF; GCSF
IL-1A IkB degradation 93-0538C15     IL1A ; IL-1A; IL1; IL1-ALPHA; IL1F1
IL-1A IL-1R1/IL-1RAP 93-1032C3   93-1032E3CP5M IL1A ; IL-1A; IL1; IL1-ALPHA; IL1F1
IL-1B IkB degradation 93-0538C15     IL1B ; IL-1; IL1-BETA; IL1F2
IL-1B IL-1R1/IL-1RAP 93-1032C3   93-1032E3CP5M IL1B ; IL-1; IL1-BETA; IL1F2
IL-1F10 - Contact Us     IL1F10 ; FIL1-theta; IL-1HY2; IL-38;
IL1-theta; IL1HY2
IL-1RN IkB degradation 93-0538C15     IL1RN ; DIRA; ICIL-1RA; IL-1RN;
IL-1ra; IL-1ra3; IL1F3; IL1RA; IRAP; MVCD4
IL-1RN IL-1R1/IL-1RAP 93-1032C3 93-1032Y3-00105
93-1032E3CP5M IL1RN ; DIRA; ICIL-1RA; IL-1RN; IL-1ra; IL-1ra3; IL1F3; IL1RA; IRAP; MVCD4
IL-2 IL-2RB /IL-2RG 93-0998C3   93-0998E3CP5M IL2 ; IL-2; TCGF; lymphokine
IL-2 IL-2RB/IL-2RG/IL-2RA 93-1003C3 93-1003Y3-00091
93-1003E3CP0M IL2 ; IL-2; TCGF; lymphokine
IL-3 IL-3R/CSF2RB 93-0969C1     IL3 ; IL-3; MCGF; MULTI-CSF
IL-4 IL-4R/IL-2RG 93-0988C3   93-0988E3CP5M IL4 ; BCGF-1; BCGF1; BSF-1; BSF1; IL-4
IL-4 IL-4R/ IL-13R 93-1000C3   93-1000E3CP5M IL4 ; BCGF-1; BCGF1; BSF-1; BSF1; IL-4
IL-4 IL-4R/ IL-13R 93-1001C1   93-1001E1CP0M IL4 ; BCGF-1; BCGF1; BSF-1; BSF1; IL-4
IL-5 IL-5R/CSF2RB 93-0972C3   93-0972E3CP0M IL5 ; EDF; IL-5; TRF
IL-6  IL-6RA /IL-6ST 93-1045C3 93-1045Y3-00043
93-1045E3CP5M IL6 ; BSF2; HGF; HSF; IFNB2; IL-6
IL-7 IL-7R/IL-2RG 93-0997C13   93-0997E13CP0M IL7 ; IL-7
IL-8 CXCR2  93-0202C2   93-0202E2CP0M CXCL8 ; GCP-1; GCP1; IL8; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1
IL-8 CXCR1 93-0226C3   93-0226E3CP0M CXCL8 ; GCP-1; GCP1; IL8; LECT; LUCT; LYNAP; MDNCF; MONAP; NAF; NAP-1; NAP1
IL-9 IL-9R/IL-2RG 93-1036C1     IL9 ; HP40; IL-9; P40
IL-10 IL-10RA/IL-10RB 93-0985C3   93-0985E3CP0M IL10 ; CSIF; GVHDS; IL-10; IL10A; TGIF
IL-11 IL-11R/IL-6ST 93-1028C1     IL11 ; AGIF; IL-11
IL-12 IL-12RB1/IL-12RB2 93-1041C3     IL12, p70
IL-13 IL-4R/IL-13R 93-1000C3   93-1000E3CP5M IL13 ; IL-13; P600
IL-13 IL-4R/IL-13R 93-1001C1   93-1001E1CP0M IL13 ; IL-13; P600
IL-14 - Contact Us     TXLNA ; IL14; TXLN
IL-15 IL-2RB/IL-2RG 93-0998C3   93-0998E3CP5M IL15 ; IL-15
IL-15 IL-2RB/IL-2RG/IL-15RA Contact Us     IL15 ; IL-15
IL-16 - Contact Us     IL16 ; LCF; NIL16; PRIL16; prIL-16
IL-17A IL-17RA/IL-17RC 93-0999C3 93-0999Y3-00053
93-0999E3CP0M IL17A ; CTLA8; IL-17; IL-17A; IL17
IL-17A/F IL-17RA/IL-17RC 93-0999C3   93-0999E3CP0M IL-17A/F
IL-17B - Contact Us      
IL-17C - Contact Us      
IL-17D - Contact Us      
IL-17E - Contact Us     IL25 ; IL17E
IL-17F IL-17RA/IL-17RC 93-0999C3   93-0999E3CP0M IL-17F
IL-18 IL-18R/IL-18RAcP 93-1044C3     IL18 ; IGIF; IL-18; IL-1g; IL1F4
IL-19 IL-20R1/IL-20R2 93-1027C3     IL19 ; IL-10C; MDA1; NG.1; ZMDA1
IL-20 IL-20R1/IL-20R2 93-1027C3     IL20 ; IL-20; IL10D; ZCYTO10
IL-20 IL-22R/IL-20R2 Contact Us     IL20 ; IL-20; IL10D; ZCYTO10
IL-21 IL-21R/IL-2RG 93-1035C3     IL21 ; CVID11; IL-21; Za11
IL-22 IL-22R/IL-10RB  93-1026C1     IL22 ; IL-21; IL-22; IL-D110; IL-TIF;
ILTIF; TIFIL-23; TIFa; zcyto18
IL-23 IL-23R/IL-12RB1 93-1007C3   93-1007E3CP0M IL23A ; IL-23; IL-23A; IL23P19; P19;
IL-24 IL-20R1/IL-20R2 93-1027C3     IL24 ; C49A; FISP; IL10B; MDA7; MOB5; ST16
IL-24 IL-22R/IL-20R2 Contact Us     IL24 ; C49A; FISP; IL10B; MDA7; MOB5; ST16
IL-26 IL-20R1/IL-10RB 93-1020C3   93-1020E3CP0M IL26 ; AK155; IL-26
IL-27 IL27RA /IL6ST 93-1119C3     IL30, p28
IL-28A IFNLR1/IL-10RB 93-0993C3    93-0993E3CP5M IL28A, IFNL2
IL-28B IFNLR1/IL-10RB 93-0993C3    93-0993E3CP5M IL28B, IFNL3
IL-29 IFNLR1/IL-10RB 93-0993C3    93-0993E3CP5M IFNL1 ; IL-29; IL29
IL-31 IL-31RA/OSMRb 93-1002C3 93-1002Y3-00083
93-1002E3CP5M IL31 ; IL-31
IL-32 - Contact Us     IL32 ; IL-32alpha; IL-32beta;
IL-32delta; IL-32gamma; NK4; TAIF; TAIFa; TAIFb; TAIFc; TAIFd
IL-33 IL1RL1 (ST2)/IL-1RAP 93-1067C3     IL33 ; C9orf26; DVS27; IL1F11;
NF-HEV; NFEHEV; RP11-575C20.2
IL-34 CSF1R/CSF1R 93-1061C3     IL34 ; C16orf77; IL-34
IL-35 IL-12RB2/IL-6ST Contact Us     IL-35
IL-36A IL1RL2/IL1RAP Contact Us     IL36A ; FIL1; FIL1(EPSILON); FIL1E; IL-1F6; IL1(EPSILON); IL1F6
IL-36B IL1RL2/IL1RAP Contact Us     IL36B ; FIL1; FIL1-(ETA); FIL1H; FILI-(ETA); IL-1F8; IL-1H2; IL1-ETA; IL1F8; IL1H2
IL-36C IL1RL2/IL1RAP Contact Us     IL36G ; IL-1F9; IL-1H1; IL-1RP2; IL1E;
IL1F9; IL1H1; IL1RP2
IL-36RN IL1RL2/IL1RAP Contact Us     IL-36RA; IL36RA
IL-37 IL18R /SIGIRR Contact Us     IL37 ; FIL1; FIL1(ZETA); FIL1Z; IL-1F7; IL-1H; IL-1H4; IL-1RP1; IL-37; IL1F7; IL1H4; IL1RP1
NP - Contact Us     Neuropoietin
M-CSF CSF1R/CSF1R 93-1061C3     CSF1 ; CSF-1; MCSF
OSM OSMRb/IL-6ST 93-1056C3     OSM ; MGC20461
TSLP IL-7R/TSLP-R 93-1019C13     TSLP

Dimerization Assay Principle

One receptor in the dimer pair is tagged with the PK fragment of the β-gal reporter, while the second receptor is fused to the EA component of β-gal. When the ligand engages the receptors, it causes it to functionally dimerize with its heterodimer partner, bringing the fragments of the β-gal reporter into close proximity. This forces complementation, creating an active enzyme that hydrolyzes substrate to generate chemiluminescence.